2-(3,5-bis(trifluoromethyl)phenyl)quinazolin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(3,5-bis(trifluoromethyl)phenyl)quinazolin-4-amine
• 英文别名: 2-[3,5-Bis(trifluoromethyl)phenyl]quinazolin-4-amine；2-[3,5-bis(trifluoromethyl)phenyl]quinazolin-4-amine
• 化学式: C₁₆H₉F₆N₃
• 分子量: 357.258
• InChiKey: FSSRZPXZKVOWJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  25
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-氟苯腈 、 3,5-bis-trifluoromethylbenzamidine 在 potassium tert-butylate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 16.0h， 以20%的产率得到2-(3,5-bis(trifluoromethyl)phenyl)quinazolin-4-amine
  参考文献：
  名称：

  Synthesis of quinazolinimines and quinazolinamines from 2-fluorobenzonitriles under catalyst-free conditions

  摘要：

  已开发出一种从2-氟苯甲腈和2-氨基吡啶或酰胺与KO^tBu作为催化剂合成喹唑啉胺和喹唑啉胺的便捷程序。

  DOI：

  10.1039/c5ob01587a

文献信息

• QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS
  申请人：GPC Biotech AG

  公开号：EP1673346A1

  公开（公告）日：2006-06-28
• Quinazoline derivatives for the treatment of herpesviral infections
  申请人：Herget Thomas

  公开号：US20070123537A1

  公开（公告）日：2007-05-31

  The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by HCMV.
• [EN] QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS<br/>[FR] DERIVES DE QUINAZOLINE POUR LE TRAITEMENT D'INFECTIONS VIRALES HERPETIQUES
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2005040125A1

  公开（公告）日：2005-05-06

  The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by HCMV.